368 related articles for article (PubMed ID: 26077324)
21. Treatment Options in Intractable Restless Legs Syndrome/Willis-Ekbom Disease (RLS/WED).
Rinaldi F; Galbiati A; Marelli S; Ferini Strambi L; Zucconi M
Curr Treat Options Neurol; 2016 Feb; 18(2):7. PubMed ID: 26874840
[TBL] [Abstract][Full Text] [Related]
22. Clinical pharmacology and efficacy of rotigotine (Neupro® patch) in the treatment of restless leg syndrome.
Ferini-Strambi L; Marelli S; Galbiati A
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):967-75. PubMed ID: 27224246
[TBL] [Abstract][Full Text] [Related]
23. Differential Diagnoses of Restless Legs Syndrome/Willis-Ekbom Disease: Mimics and Comorbidities.
Chokroverty S
Sleep Med Clin; 2015 Sep; 10(3):249-62, xii. PubMed ID: 26329435
[TBL] [Abstract][Full Text] [Related]
24. Restless Leg Syndrome/Willis-Ekbom Disease Pathophysiology.
Allen RP
Sleep Med Clin; 2015 Sep; 10(3):207-14, xi. PubMed ID: 26329430
[TBL] [Abstract][Full Text] [Related]
25. Consensus clinical practice guidelines for the diagnosis and treatment of restless legs syndrome/Willis-Ekbom disease during pregnancy and lactation.
Picchietti DL; Hensley JG; Bainbridge JL; Lee KA; Manconi M; McGregor JA; Silver RM; Trenkwalder C; Walters AS;
Sleep Med Rev; 2015 Aug; 22():64-77. PubMed ID: 25553600
[TBL] [Abstract][Full Text] [Related]
26. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.
Wanner V; Garcia Malo C; Romero S; Cano-Pumarega I; García-Borreguero D
Adv Pharmacol; 2019; 84():187-205. PubMed ID: 31229171
[TBL] [Abstract][Full Text] [Related]
27. [Restless legs: recent advances in basic research and therapy].
Sieb JP
Med Monatsschr Pharm; 2010 Apr; 33(4):133-9. PubMed ID: 20429403
[TBL] [Abstract][Full Text] [Related]
28. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
[TBL] [Abstract][Full Text] [Related]
29. The Parkinson's disease and restless legs syndrome/Willis-Ekbom disorder link: evidences, biases and clinical relevance.
Munhoz RP; Constantino MCL; Silveira-Moriyama L
Arq Neuropsiquiatr; 2019 Jan; 77(1):47-54. PubMed ID: 30758442
[TBL] [Abstract][Full Text] [Related]
30. Dopaminergic augmentation of restless legs syndrome.
García-Borreguero D; Williams AM
Sleep Med Rev; 2010 Oct; 14(5):339-46. PubMed ID: 20219397
[TBL] [Abstract][Full Text] [Related]
31. The prevalence of the restless legs Syndrome/Willis-Ekbom disease among teenagers, its clinical characteristics and impact on everyday functioning.
Pienczk-Ręcławowicz K; Pilarska E; Olszewska A; Ręcławowicz D; Konieczna S; Sławek J
Sleep Med; 2022 Jan; 89():48-54. PubMed ID: 34883398
[TBL] [Abstract][Full Text] [Related]
32. D3 receptor agonist efficacy in restless legs syndrome.
Casoni F; Galbiati A; Ferini-Strambi L
Adv Pharmacol; 2019; 84():21-35. PubMed ID: 31229173
[TBL] [Abstract][Full Text] [Related]
33. A prospective study of Willis-Ekbom disease/restless legs syndrome during and after pregnancy.
Neyal A; Senel GB; Aslan R; Nalbantoglu M; Acikgoz S; Yilmaz N; Tumay FB; Neyal M; Karadeniz D
Sleep Med; 2015 Sep; 16(9):1036-40. PubMed ID: 26298776
[TBL] [Abstract][Full Text] [Related]
34. Advancing synthetic therapies for the treatment of restless legs syndrome.
de Biase S; Pellitteri G; Gigli GL; Valente M
Expert Opin Pharmacother; 2019 Nov; 20(16):1971-1980. PubMed ID: 31424287
[No Abstract] [Full Text] [Related]
35. Altered brain iron homeostasis and dopaminergic function in Restless Legs Syndrome (Willis-Ekbom Disease).
Earley CJ; Connor J; Garcia-Borreguero D; Jenner P; Winkelman J; Zee PC; Allen R
Sleep Med; 2014 Nov; 15(11):1288-301. PubMed ID: 25201131
[TBL] [Abstract][Full Text] [Related]
36. Restless Leg Syndrome Across the Globe: Epidemiology of the Restless Legs Syndrome/Willis-Ekbom Disease.
Koo BB
Sleep Med Clin; 2015 Sep; 10(3):189-205, xi. PubMed ID: 26329429
[TBL] [Abstract][Full Text] [Related]
37. A review of current treatment strategies for restless legs syndrome (Willis-Ekbom disease).
Klingelhoefer L; Cova I; Gupta S; Chaudhuri KR
Clin Med (Lond); 2014 Oct; 14(5):520-4. PubMed ID: 25301914
[TBL] [Abstract][Full Text] [Related]
38. Restless Legs Syndrome/Willis-Ekbom Disease Morbidity: Burden, Quality of Life, Cardiovascular Aspects, and Sleep.
Stevens MS
Sleep Med Clin; 2015 Sep; 10(3):369-73, xv-xvi. PubMed ID: 26329447
[TBL] [Abstract][Full Text] [Related]
39. Prevalence and quality of life and sleep in children and adolescents with restless legs syndrome/Willis-Ekbom disease.
Sander HH; Eckeli AL; Costa Passos AD; Azevedo L; Fernandes do Prado LB; França Fernandes RM
Sleep Med; 2017 Feb; 30():204-209. PubMed ID: 28215250
[TBL] [Abstract][Full Text] [Related]
40. Quantitative sensory test for primary restless legs syndrome/Willis-Ekbom disease using the current perception threshold test.
Cho YW; Kang MS; Kim KT; Do SY; Lim JG; Lee SY; Motamedi GK
Sleep Med; 2017 Feb; 30():19-23. PubMed ID: 28215248
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
